News

Article

Preclinical study of KIO-104 in a proliferative vitreoretinopathy model accepted for poster presentation at ARVO 2025

Author(s):

Key Takeaways

  • KIO-104 effectively reduces scar formation and retinal detachment in a PVR rabbit model, indicating its therapeutic potential.
  • The small molecule DHODH inhibitor suppresses T cell division and function, targeting inflammation in PVR.
SHOW MORE

The findings of this model support KIO-104 as a promising therapeutic candidate for both the prevention and treatment of PVR.

(Image Credit: AdobeStock/Mr image)

(Image Credit: AdobeStock/Mr image)

An abstract of a preclinical study of KIO-104 in a proliferative vitreoretinopathy (PVR) model was accepted for poster presentation at the Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, UT, May 4-8, 2025. The findings of this model support KIO-104 as a promising therapeutic candidate for both the prevention and treatment of PVR.1

In the press release1, Kiora Pharmaceuticals shared that the presentation will be titled, "KIO-104, a novel small molecule inhibitor of DHODH, effectively prevents proliferative vitreoretinopathy in a rabbit model." It will be presented by Romana Seda-Zehetner, MSc MSc Tox, Kiora's Director, Preclinical Development.

Presentation details

  • Presentation number: 218 - A0485
  • Session title: Vitreoretinal surgery and retinal detachment I
  • Date: May 4, 2025
  • Time: 8:00 AM to 9:45 AM Mountain Standard Time

The study evaluated the effect of KIO-104 at multiple dose levels on the reduction of both scar formation and magnitude in an established model of retinal detachment. Clinically, PVR is characterized by scar formation and subsequent retinal detachment.1

KIO-104 is a small molecule DHODH inhibitor that works by suppressing T cell division and function. Suppressing T cells in PVR could provide a novel approach to reducing or eliminating inflammation that often leads to scar formation. KIO-104 is being evaluated in a Phase 2 clinical trial in patients with macular edema, an inflammation driven condition secondary to several conditions including diabetic retinopathy and posterior non-infectious uveitis.

Reference:
  1. Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual Meeting. Kiora Pharmaceuticals. March 12, 2025. Accessed March 16, 2025. https://www.streetinsider.com/Newsfile/Kiora+Pharmaceuticals+to+Present+Preclinical+Data+on+KIO-104+for+the+Treatment+of+Proliferative+Vitreoretinopathy+at+the+ARVO+2025+Annual+Meeting/24488038.html

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
© 2025 MJH Life Sciences

All rights reserved.